Skip to main content
Increase in the Amount Allocated to the Liquidity Contract
April 15, 2025
Phase 3 Survey Results Demonstrate Patient and Healthcare Professional Satisfaction with Olanzapine LAI
March 31, 2025
Medincell Strengthens its Board of Directors
March 6, 2025
Presentation at the TD Cowen 45th Annual Healthcare Conference
February 26, 2025
FDA Acceptance of Supplemental New Drug Application for UZEDY® as a Treatment for Patients with Bipolar I Disorder
February 25, 2025
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia
February 10, 2025
The EIB Reaffirms Confidence in Medincell by Permanently Waiving Two Financial Covenants in its Loan Agreement
February 6, 2025
UZEDY® Surges to $117M in Sales in 2024, First Full Year of Commercialization
January 29, 2025
